Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.

doi:10.1002/jpn3.12045

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.

Journal of pediatric gastroenterology and nutrition - 1 Jun 2024

Jonas Maureen M, Romero Rene, Rosenthal Philip, Lin Chuan-Hao, Verucchi Gabriella, Wen Jessica, Balistreri William F, Whitworth Suzanne, Bansal Sanjay, Leung Daniel H, Narkewicz Michael R, Gonzalez-Peralta Regino P, Mangia Alessandra, Karnsakul Wikrom, Rao Girish S, Shao Jiang, de Jong Jan, Parhy Bandita, Osinusi Anu, Kersey Kathryn, Murray Karen F, Sokal Etienne M, Schwarz Kathleen B

Abstract excerpt

BACKGROUND: The safety and efficacy of sofosbuvir-velpatasvir in children aged 3-17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated. METHODS: In this Phase 2, multicenter, open-label study, patients received once daily for 12 weeks either sofosbuvir-velpatasvir 400/100 mg tablet (12-17 years), 200/50 mg low dose tablet or oral granules (3-11 years and ≥17 kg), or 150/37.5 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzopyrans

Share to Carbamates

Share to Drug Combinations

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 4 or More Rings

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Open in PubMed

Identifiers

PMID: 38644678
DOI: 10.1002/jpn3.12045

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.PMID 38644678Read ↗

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionSemantic proximity Read ↗

Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infectionSemantic proximity Read ↗

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.Semantic proximity Read ↗

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.Semantic proximity Read ↗

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.Semantic proximity Read ↗

Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.Semantic proximity Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.Semantic proximity Read ↗

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.Semantic proximity Read ↗

Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents.Semantic proximity Read ↗

[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.